SARM Compounds Preserve Lean Mass During Weight Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Weight loss drugs like GLP-1 receptor agonists and SGLT-2 inhibitors cause significant loss of both fat and lean body mass, leading to safety concerns such as muscle weakness, decreased physical function, and increased risk of falls and fractures.
Innovation Solution
Administering a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, represented by specific structures, to prevent, reduce, or treat adverse effects caused by weight loss drugs, including preserving or increasing lean body mass and decreasing fat mass.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If weight loss drugs (GLP-1 RAs or SGLT-2 inhibitors) are administered to reduce body weight, then fat mass is decreased, but lean body mass is also lost leading to muscle weakness and decreased physical function
Solution Approach 1:
The patent applies local quality by developing SARM compounds that selectively target androgen receptors in muscle tissue to preserve lean body mass, while allowing weight loss drugs to continue their fat mass reduction effects. This selective action at the tissue level resolves the contradiction by protecting muscle strength locally without interfering with overall weight loss.
Solution Approach 2:
The SARM compounds act as intermediary substances that mediate between the weight loss drugs and muscle tissue. The SARMs bind to androgen receptors in muscle, serving as a protective intermediary that prevents muscle catabolism caused by weight loss drugs, thereby maintaining muscle strength while allowing fat mass reduction to proceed.
2Quantity of substance
If weight loss drugs are administered to reduce body weight, then overall weight is decreased, but physical function deteriorates due to loss of lean body mass
Solution Approach 1:
The SARM compounds provide local quality protection to muscle tissue through selective androgen receptor modulation. This ensures that physical function is maintained in muscle tissues specifically, while allowing overall body weight reduction to occur through fat mass loss, thus resolving the contradiction between weight loss and physical function preservation.
Solution Approach 2:
The patent segments the body composition effects by using SARM compounds to specifically protect lean body mass while allowing fat mass to be reduced by weight loss drugs. This segmentation of effects allows independent control of fat loss and muscle preservation, resolving the contradiction between weight reduction and physical function maintenance.
3Quantity of substance
If weight loss drugs are administered to achieve chronic weight management, then fat mass is reduced, but bone density and muscle mass are compromised increasing risk of falls and fractures
Solution Approach 1:
The SARM compounds apply local quality protection to bone and muscle tissues through selective androgen receptor activation. This localized protection maintains bone density and muscle mass integrity in specific tissues, while allowing systemic fat mass reduction to proceed, thereby resolving the contradiction between weight management and structural integrity preservation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of SARM compounds effectively mitigates the loss of lean body mass and muscle strength associated with weight loss drugs, while also promoting healthy weight loss and improving body composition.
Implementation Method 1
administering a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound to prevent, reduce, or treat adverse effects caused by weight loss drugs
Implementation Method 2
decreasing fat mass while preserving or increasing lean mass
Data Source
AI summary
The present invention provides methods and compositions for preventing, reducing, or treating adverse effects caused by an incretin agonist or antagonist containing weight loss drug or a sodium-glucose transport protein 2 (SGLT-2) inhibitor in a subject who is under treatment with the incretin agonist or antagonist containing weight loss drug or SGLT-2 inhibitor. The method comprises coadministering or administering after discontinuation of the incretin agonist or antagonist containing weight loss drug or SGLT-2 inhibitor to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound represented by a structure of Formulas I, II, VIII, IX, X, XI, XII, XIII, and XIV disclosed herein to the subject under incretin agonist or antagonist containing drug or SGLT-2 agent therapy.